These results suggest that R/R MM patients with extramedullary disease who respond to anti-BCMA CAR T cell therapy can use this time as a bridge to other treatments, such as HSCT, radiotherapy, and other therapies. The gene discussed is TNFRSF17; the disease is glycogen storage disease VI.